Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Blair C. Jackson

CEOBlair C. Jackson

Employees

2,050

Employees2,050

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,050

Employees2,050

ALKS Key Statistics

Market cap

7.76B

Market cap7.76B

Price-Earnings ratio

119.74

Price-Earnings ratio119.74

Dividend yield

—

Dividend yield—

Average volume

1.30M

Average volume1.30M

High today

$46.53

High today$46.53

Low today

$44.68

Low today$44.68

Open price

$45.10

Open price$45.10

Volume

769.18K

Volume769.18K

52 Week high

$55.67

52 Week high$55.67

52 Week low

$25.17

52 Week low$25.17

Stock Snapshot

Alkermes(ALKS) stock is priced at $46.28, giving the company a market capitalization of 7.76B. It carries a P/E multiple of 119.74.

As of 2026-09-08, Alkermes(ALKS) stock has fluctuated between $44.68 and $46.53. The current price stands at $46.28, placing the stock +3.6% above today's low and -0.5% off the high.

Alkermes(ALKS) shares are trading with a volume of 769.18K, against a daily average of 1.3M.

In the last year, Alkermes(ALKS) shares hit a 52-week high of $55.67 and a 52-week low of $25.17.

ALKS News

Simply Wall St 2d

Should Alkermes’ Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st

...

Simply Wall St 3d

Alkermes Following Favorable Alixorexton Data Is The Orexin Story Already Priced In

Alkermes (ALKS) stock is drawing fresh attention after the company reported favorable phase 2 Vibrance-1 data for its orexin 2 receptor agonist alixorexton in n...

TipRanks 4d

Mizuho survey shows no consensus into Alkermes ADHD data

Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, which is expe...

Analyst ratings

72%

of 18 ratings

Buy

72.2%

Hold

22.2%

Sell

5.6%

More ALKS News

Simply Wall St 4d

Alkermes Started Phase 3 Trials For Alixorexton In Narcolepsy Type 1

Alkermes (NasdaqGS: ALKS) reported positive phase 2 results for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1, and announced the start of glo...

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.